-
Mashup Score: 4Narjust Duma on Advanced NSCLC Reducing Racial Disparities in Outcomes - The ASCO Post - 2 year(s) ago
2021 Multidisciplinary Thoracic Cancers Symposium Narjust Duma, MD, of Dana-Farber Cancer Institute, discusses the many factors that lead to poorer outcomes in lower-income and minority patients with advanced non–small cell lung cancer and the urgent need to address these disparities and physician bias. Women of color and other minority patients are…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Mirek Fatyga on NSCLC New Data on Stereotactic Body Radiotherapy vs Conventionally Fractionated Radiotherapy - The ASCO Post - 2 year(s) ago
2021 Multidisciplinary Thoracic Cancers Symposium Mirek Fatyga, PhD, of Mayo Clinic Arizona, discusses his findings on overall survival in patients with locally advanced non–small cell lung cancer who are treated with stereotactic body radiotherapy or conventionally fractionated radiotherapy. He notes that a high dose of > 50 Gy to the…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Mirek Fatyga, PhD, on NSCLC: New Data on Stereotactic Body Radiotherapy vs Conventionally Fractionated Radiotherapy https://t.co/JJY5vYhIXp #LCSM #oncology #cancer #radonc #thoracic21 @MayoClinic https://t.co/twoboNVkOs
-
-
Mashup Score: 1
Julia Rotow, MD, on Patient Selection in Treating Thoracic Cancers: Looking to Driver Mutations and Biomarkers Julia Rotow, MD, of Dana-Farber Cancer Institute, discusses an education session she conducted on mutations and biomarkers in thoracic cancers, including PD-L1, a continuous variable, with the greatest benefit to treatment being…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Carolyn Presley, MD, on Dementia in Patients Treated for Thoracic Cancer https://t.co/U918NqlvVW #thoracic21 @ASTRO_org @ASCO @STS_CTsurgery @sitcancer @CPresGeriOncMD @OSUCCC_James @OSUWexMed https://t.co/pkD5doSWbM
-
-
Mashup Score: 0Julia Rotow on Patient Selection in Treating Thoracic Cancers Looking to Driver Mutations and Biomarkers - The ASCO Post - 2 year(s) ago
2021 Multidisciplinary Thoracic Cancers Symposium Julia Rotow, MD, of Dana-Farber Cancer Institute, discusses an education session she conducted on mutations and biomarkers in thoracic cancers, including PD-L1, a continuous variable, with the greatest benefit to treatment being associated with very high levels of PD-L1 tissue polypeptide-specific antigen. Dr….
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Julia Rotow, MD, on Patient Selection in Treating Thoracic Cancers: Looking to Driver Mutations and Biomarkers https://t.co/NcJSnjAZZK @JuliaRotow #thoracic21 @ASTRO_org @ASCO @STS_CTsurgery @sitcancer https://t.co/OkdZnbXW3g
-
-
Mashup Score: 0HOME - NSCLC Tumor Board: Multimodal Approaches to Optimize Immune Checkpoint Inhibition Strategies in Curative Settings - 2 year(s) ago
NSCLC Tumor Board: Multimodal Approaches to Optimize Immune Checkpoint Inhibition Strategies in Curative Settings.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join renowned experts in thoracic oncology for a PER® Tumor Board satellite symposium on NSCLC. Register now and earn CME/CE credit after participating: https://t.co/GNafirP8Hc #gotoPER #NSCLC #lcsm #THORACIC21 @HwakeleeMD https://t.co/SUgnpvJiOM
-
-
Mashup Score: 0HOME - NSCLC Tumor Board: Multimodal Approaches to Optimize Immune Checkpoint Inhibition Strategies in Curative Settings - 2 year(s) ago
NSCLC Tumor Board: Multimodal Approaches to Optimize Immune Checkpoint Inhibition Strategies in Curative Settings.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Earn complimentary CME/CE credits during the Satellite Symposium: NSCLC Tumor Board. This program brings together renowned experts in thoracic oncology and offers networking opportunities. Register now: https://t.co/1XnQOmPTwQ #gotoPER #NSCLC #lcsm #THORACIC21 @HwakeleeMD https://t.co/mSyyTuSeNa
-
-
Mashup Score: 1Thoracic Symposium starts tomorrow, Cast your bylaws vote, 2022 Minority Summer Fellowship - 2 year(s) ago
December 1, 2021 …
Source: www.magnetmail.netCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New in the #ASTROgram: #Thoracic21 Symposium starts tomorrow, cast your bylaws vote, 2022 Minority Summer Fellowship, #ASTROadvocacy continues year-end push to block Medicare cuts, new #ASTROacademy courses and more. Read the latest #RadOnc news here: https://t.co/jxJNz2CHsN https://t.co/28BeQnAyeE
-
-
Mashup Score: 0HOME - NSCLC Tumor Board: Multimodal Approaches to Optimize Immune Checkpoint Inhibition Strategies in Curative Settings - 2 year(s) ago
NSCLC Tumor Board: Multimodal Approaches to Optimize Immune Checkpoint Inhibition Strategies in Curative Settings.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
There’s still time to register and earn complimentary CME/CE credits for this satellite symposium on December 1. Secure your spot now: https://t.co/7MZXIGTmBU #gotoPER #NSCLC #lcsm #THORACIC21 https://t.co/RA8CHlgzIN
-
-
Mashup Score: 2
Discover the 2021 symposium program including abstracts, schedule of events, and continuing education credits.
Source: www.astro.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Thoracic21 is just a few short days away! To prepare, check out our short presenter videos, where you can learn more about the research and topics they will be presenting and why you should attend: https://t.co/NQjQ2utDXN #RadOnc @ASCO @sitcancer @STS_CTsurgery https://t.co/Y6pYRaMDni
-
-
Mashup Score: 0HOME - NSCLC Tumor Board: Multimodal Approaches to Optimize Immune Checkpoint Inhibition Strategies in Curative Settings - 2 year(s) ago
NSCLC Tumor Board: Multimodal Approaches to Optimize Immune Checkpoint Inhibition Strategies in Curative Settings.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Earn complimentary CME/CE credits during the Satellite Symposium: NSCLC Tumor Board. This program brings together renowned experts in thoracic oncology and offers networking opportunities. Register now: https://t.co/GNafirP8Hc #gotoPER #NSCLC #lcsm #THORACIC21 https://t.co/qrI3Du9ibQ
-
Did you know that most patients with lung cancer receive diagnoses of advanced disease and face poor survival outcomes? This satellite symposium offers ways to improve outcomes for your patients with NSCLC. Register now: https://t.co/7MZXIHaXts #gotoPER #NSCLC #lcsm #THORACIC21 https://t.co/eLC6HuyygQ
-
Narjust Duma, MD, on Advanced NSCLC: Reducing Racial Disparities in Outcomes https://t.co/a5umwuBGXW @NarjustDumaMD #thoracic21 #LCSM #oncology #cancer #healthequity #racialdisparities https://t.co/kDzaGIeaql